Oncology Based In-Vivo CRO Market Report by Indication (Blood Cancer, Solid Tumors, and Others), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX), and Others), Application (Hospitals, Rehabilitation Centers), and Region 2026-2034
The global oncology based in-vivo CRO market size reached USD 1.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.29% during 2026-2034. The rising prevalence of cancer, regulatory compliances, ongoing technological advancements, and the surging demand for personalized medicines are driving the market growth.
ONCOLOGY BASED IN-VIVO CRO MARKET ANALYSIS:
Rising Prevalence of Cancer
The rising prevalence of cancer is a significant driver behind the growth of the oncology-based in-vivo Contract Research Organization (CRO) market. Cancer continues to be a major public health challenge worldwide, with increasing incidence rates across various types of cancers. For instance, the IARC's 2022 study showed around 20 million new cancer cases and nearly nine million deaths worldwide, with lung and breast cancer being the most common. Similarly, according to an article published by the Union for International Cancer Control, cancer cases are projected to rise to 35 million by 2050. The complexity of cancer requires tailored treatment approaches, leading to a higher demand for clinical trials and research services provided by CROs. These factors are positively influencing the oncology based in-vivo CRO market revenue.
Increasing Emphasis on Personalized Medicine
The increasing emphasis on personalized medicine is a major driver behind the growth and evolution of the oncology-based in-vivo Contract Research Organization (CRO) market. For instance, according to Statista, personalized medical care, medicines, and diagnostics were estimated to account for around 40% of total revenue in 2022. Oncology is the most significant therapeutic area for personalized medicine. Tailoring treatments to individual patients improves efficacy, reduces adverse effects, and enhances overall treatment outcomes, driving the demand for CROs with expertise in personalized medicine, thereby positively influencing the oncology based in-vivo CRO industry forecast.
Technological Advancements
Increasing technological advancements are escalating the demand for oncology-based in-vivo Contract Research Organizations. Improved imaging modalities, such as PET-CT, MRI, and molecular imaging techniques have enabled better visualization and monitoring of tumors in vivo. For instance, in June 2024, Siemens Healthineers launched the Biograph Trinion, their latest PET/CT scanner, at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging. The scanner's detector is based on lutetium oxyorthosilicate (LSO) crystal elements and delivers high spatial resolution and an ultrafast time-of-flight performance of 239 picoseconds for small lesion detectability and effective sensitivity up to 128 cps/kBq, allowing for fast scans and low patient radiation doses. This enhances the ability to track disease progression and response to treatments more accurately. These factors are further bolstering the oncology-based in-vivo CRO market revenue.
GLOBAL ONCOLOGY BASED IN-VIVO CRO INDUSTRY SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the global oncology based in-vivo CRO market report, along with forecasts at the global, regional and country levels from 2026-2034. Our report has categorized the market based on indication, model and application.
Breakup by Indication:
The report has provided a detailed breakup and analysis of the market based on the indication. This includes blood cancer, solid tumors, and others. According to the report, solid tumors represented the largest market segmentation.
According to the oncology-based in-vivo CRO market outlook, solid tumors are the most common type of cancer, encompassing a wide range of malignancies such as breast, lung, colorectal, and prostate cancers. Their prevalence ensures a large patient population for clinical trials, making them attractive for CROs and pharmaceutical companies. Moreover, there has been a significant increase in the number of cancer patients. For instance, the American Cancer Society, the major source of cancer statistics and data, estimated nearly 1,685,210 new cancer cases and 595,690 deaths in the United States in 2021.
Breakup by Model:
The report has provided a detailed breakup and analysis of the market based on the model. This includes syngeneic, xenograft, patient derived xenograft (PDX), and others. According to the report, the Patient Derived Xenograft (PDX) model accounts for the majority of the total market share.
According to the oncology-based in-vivo CRO market overview, PDX models involve implanting patient-derived tumor tissue into immunodeficient mice, thereby preserving the molecular and histological characteristics of the original tumor. This model closely mimics human tumor biology and heterogeneity, making it invaluable for studying cancer progression, metastasis, and treatment response. Moreover, these models are highly predictive of patient response to therapies, including chemotherapy, targeted therapy, and immunotherapy. Pharmaceutical companies and biotech firms rely on PDX studies to assess drug efficacy, optimize treatment regimens, and identify potential biomarkers for patient stratification.
Breakup by Application:
Hospitals frequently collaborate with CROs to conduct clinical trials for evaluating new oncology treatments. CROs provide expertise in study design, protocol development, patient recruitment, and regulatory compliance, enabling hospitals to participate in cutting-edge research without diverting resources from patient care. While rehabilitation centers may participate in clinical trials focused on cancer survivors who require rehabilitation services to improve their quality of life post-treatment. CROs can support such trials by providing expertise in study design, outcome measures, and data management specific to this patient population.
Breakup by Region:
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
According to the oncology based in-vivo CRO market statistics, the rising incidence of cancer cases in North America continues to drive demand for innovative therapies and treatment options. For instance, the Globocan 2021 report estimated that nearly 2,281,000 new cancer cases were diagnosed in the United States in 2021, with almost 612,000 fatalities. Oncology-focused CROs play a critical role in advancing research and development efforts to address unmet medical needs across various cancer types. Moreover, continuous advancements in technology, including molecular profiling, genomic sequencing, imaging modalities (such as PET-CT and MRI), and high-throughput screening platforms, enhance the capabilities of CROs to conduct sophisticated in-vivo studies. These technologies enable precise characterization of tumors, identification of biomarkers, and evaluation of therapeutic efficacy, contributing to the growth of oncology based CRO services.
COMPETITIVE LANDSCAPE:
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:
KEY QUESTIONS ANSWERED IN THIS REPORT
1. What was the size of the global oncology based in-vivo CRO market in 2025?
2. What is the expected growth rate of the global oncology based in-vivo CRO market during 2026-2034?
3. What are the key factors driving the global oncology based in-vivo CRO market?
4. What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?
5. What is the breakup of the global oncology based in-vivo CRO market based on the indication?
6. What is the breakup of the global oncology based in-vivo CRO market based on the model?
7. What are the key regions in the global oncology based in-vivo CRO market?
8. Who are the key players/companies in the global oncology based in-vivo CRO market?
ONCOLOGY BASED IN-VIVO CRO MARKET ANALYSIS:
- Major Market Drivers: The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities, which is driving industry’s growth.
- Key Market Trends: The wide availability of personalized treatment techniques, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry to ensure the safety of cancer patients. This is projected to bolster the growth of the market.
- Competitive Landscape: Some of the prominent oncology based in-vivo CRO market companies in the market include Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec, and Xentech, among many others.
- Geographical Trends: According to the oncology based in-vivo CRO market dynamics, North America exhibits a clear dominance in the market. The prevalence of various types of cancer continues to increase in the region, driving oncology based in-vivo CRO market demand.
- Challenges and Opportunities: Regulatory and compliance burden, and the increasing demand for customized clinical trial protocols are hampering the market growth. However, AI-driven algorithms for data analytics, predictive modeling, and patient stratification enhance efficiency and decision-making in oncology research.
Rising Prevalence of Cancer
The rising prevalence of cancer is a significant driver behind the growth of the oncology-based in-vivo Contract Research Organization (CRO) market. Cancer continues to be a major public health challenge worldwide, with increasing incidence rates across various types of cancers. For instance, the IARC's 2022 study showed around 20 million new cancer cases and nearly nine million deaths worldwide, with lung and breast cancer being the most common. Similarly, according to an article published by the Union for International Cancer Control, cancer cases are projected to rise to 35 million by 2050. The complexity of cancer requires tailored treatment approaches, leading to a higher demand for clinical trials and research services provided by CROs. These factors are positively influencing the oncology based in-vivo CRO market revenue.
Increasing Emphasis on Personalized Medicine
The increasing emphasis on personalized medicine is a major driver behind the growth and evolution of the oncology-based in-vivo Contract Research Organization (CRO) market. For instance, according to Statista, personalized medical care, medicines, and diagnostics were estimated to account for around 40% of total revenue in 2022. Oncology is the most significant therapeutic area for personalized medicine. Tailoring treatments to individual patients improves efficacy, reduces adverse effects, and enhances overall treatment outcomes, driving the demand for CROs with expertise in personalized medicine, thereby positively influencing the oncology based in-vivo CRO industry forecast.
Technological Advancements
Increasing technological advancements are escalating the demand for oncology-based in-vivo Contract Research Organizations. Improved imaging modalities, such as PET-CT, MRI, and molecular imaging techniques have enabled better visualization and monitoring of tumors in vivo. For instance, in June 2024, Siemens Healthineers launched the Biograph Trinion, their latest PET/CT scanner, at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging. The scanner's detector is based on lutetium oxyorthosilicate (LSO) crystal elements and delivers high spatial resolution and an ultrafast time-of-flight performance of 239 picoseconds for small lesion detectability and effective sensitivity up to 128 cps/kBq, allowing for fast scans and low patient radiation doses. This enhances the ability to track disease progression and response to treatments more accurately. These factors are further bolstering the oncology-based in-vivo CRO market revenue.
GLOBAL ONCOLOGY BASED IN-VIVO CRO INDUSTRY SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the global oncology based in-vivo CRO market report, along with forecasts at the global, regional and country levels from 2026-2034. Our report has categorized the market based on indication, model and application.
Breakup by Indication:
- Blood Cancer
- Solid Tumors
- Others
The report has provided a detailed breakup and analysis of the market based on the indication. This includes blood cancer, solid tumors, and others. According to the report, solid tumors represented the largest market segmentation.
According to the oncology-based in-vivo CRO market outlook, solid tumors are the most common type of cancer, encompassing a wide range of malignancies such as breast, lung, colorectal, and prostate cancers. Their prevalence ensures a large patient population for clinical trials, making them attractive for CROs and pharmaceutical companies. Moreover, there has been a significant increase in the number of cancer patients. For instance, the American Cancer Society, the major source of cancer statistics and data, estimated nearly 1,685,210 new cancer cases and 595,690 deaths in the United States in 2021.
Breakup by Model:
- Syngeneic
- Xenograft
- Patient Derived Xenograft (PDX)
- Others
The report has provided a detailed breakup and analysis of the market based on the model. This includes syngeneic, xenograft, patient derived xenograft (PDX), and others. According to the report, the Patient Derived Xenograft (PDX) model accounts for the majority of the total market share.
According to the oncology-based in-vivo CRO market overview, PDX models involve implanting patient-derived tumor tissue into immunodeficient mice, thereby preserving the molecular and histological characteristics of the original tumor. This model closely mimics human tumor biology and heterogeneity, making it invaluable for studying cancer progression, metastasis, and treatment response. Moreover, these models are highly predictive of patient response to therapies, including chemotherapy, targeted therapy, and immunotherapy. Pharmaceutical companies and biotech firms rely on PDX studies to assess drug efficacy, optimize treatment regimens, and identify potential biomarkers for patient stratification.
Breakup by Application:
- Hospitals
- Rehabilitation Centers
Hospitals frequently collaborate with CROs to conduct clinical trials for evaluating new oncology treatments. CROs provide expertise in study design, protocol development, patient recruitment, and regulatory compliance, enabling hospitals to participate in cutting-edge research without diverting resources from patient care. While rehabilitation centers may participate in clinical trials focused on cancer survivors who require rehabilitation services to improve their quality of life post-treatment. CROs can support such trials by providing expertise in study design, outcome measures, and data management specific to this patient population.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
According to the oncology based in-vivo CRO market statistics, the rising incidence of cancer cases in North America continues to drive demand for innovative therapies and treatment options. For instance, the Globocan 2021 report estimated that nearly 2,281,000 new cancer cases were diagnosed in the United States in 2021, with almost 612,000 fatalities. Oncology-focused CROs play a critical role in advancing research and development efforts to address unmet medical needs across various cancer types. Moreover, continuous advancements in technology, including molecular profiling, genomic sequencing, imaging modalities (such as PET-CT and MRI), and high-throughput screening platforms, enhance the capabilities of CROs to conduct sophisticated in-vivo studies. These technologies enable precise characterization of tumors, identification of biomarkers, and evaluation of therapeutic efficacy, contributing to the growth of oncology based CRO services.
COMPETITIVE LANDSCAPE:
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:
- Champions Oncology Inc.
- Charles River Laboratories International Inc.
- Crown Bioscience Inc.
- Eurofins Scientific
- Evotec SE
- ICON Plc
- Labcorp Drug Development (Laboratory Corporation of America Holdings)
- Living Tumor Laboratory
- Taconic Biosciences Inc.
- The Jackson Laboratory
- WuXi AppTec
- Xentech
KEY QUESTIONS ANSWERED IN THIS REPORT
1. What was the size of the global oncology based in-vivo CRO market in 2025?
2. What is the expected growth rate of the global oncology based in-vivo CRO market during 2026-2034?
3. What are the key factors driving the global oncology based in-vivo CRO market?
4. What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?
5. What is the breakup of the global oncology based in-vivo CRO market based on the indication?
6. What is the breakup of the global oncology based in-vivo CRO market based on the model?
7. What are the key regions in the global oncology based in-vivo CRO market?
8. Who are the key players/companies in the global oncology based in-vivo CRO market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY INDICATION
6.1 Blood Cancer
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Solid Tumors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 MARKET BREAKUP BY MODEL
7.1 Syngeneic
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Xenograft
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Patient Derived Xenograft (PDX)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY APPLICATION
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Rehabilitation Centers
8.2.1 Market Trends
8.2.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Champions Oncology Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Charles River Laboratories International Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Crown Bioscience Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Eurofins Scientific
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Evotec SE
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 ICON Plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.8 Living Tumor Laboratory
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Taconic Biosciences Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 The Jackson Laboratory
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.11 WuXi AppTec
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.12 Xentech
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY INDICATION
6.1 Blood Cancer
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Solid Tumors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 MARKET BREAKUP BY MODEL
7.1 Syngeneic
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Xenograft
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Patient Derived Xenograft (PDX)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY APPLICATION
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Rehabilitation Centers
8.2.1 Market Trends
8.2.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Champions Oncology Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Charles River Laboratories International Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Crown Bioscience Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Eurofins Scientific
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Evotec SE
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 ICON Plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.8 Living Tumor Laboratory
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Taconic Biosciences Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 The Jackson Laboratory
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.11 WuXi AppTec
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.12 Xentech
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
LIST OF TABLES
Table 1: Global: Oncology Based In-Vivo CRO Market: Key Industry Highlights, 2025 and 2034
Table 2: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Indication (in Million USD), 2026-2034
Table 3: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Model (in Million USD), 2026-2034
Table 4: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Application (in Million USD), 2026-2034
Table 5: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Region (in Million USD), 2026-2034
Table 6: Global: Oncology Based In-Vivo CRO Market: Competitive Structure
Table 7: Global: Oncology Based In-Vivo CRO Market: Key Players
Table 1: Global: Oncology Based In-Vivo CRO Market: Key Industry Highlights, 2025 and 2034
Table 2: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Indication (in Million USD), 2026-2034
Table 3: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Model (in Million USD), 2026-2034
Table 4: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Application (in Million USD), 2026-2034
Table 5: Global: Oncology Based In-Vivo CRO Market Forecast: Breakup by Region (in Million USD), 2026-2034
Table 6: Global: Oncology Based In-Vivo CRO Market: Competitive Structure
Table 7: Global: Oncology Based In-Vivo CRO Market: Key Players
LIST OF FIGURES
Figure 1: Global: Oncology Based In-Vivo CRO Market: Major Drivers and Challenges
Figure 2: Global: Oncology Based In-Vivo CRO Market: Sales Value (in Billion USD), 2020-2025
Figure 3: Global: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Billion USD), 2026-2034
Figure 4: Global: Oncology Based In-Vivo CRO Market: Breakup by Indication (in %), 2025
Figure 5: Global: Oncology Based In-Vivo CRO Market: Breakup by Model (in %), 2025
Figure 6: Global: Oncology Based In-Vivo CRO Market: Breakup by Application (in %), 2025
Figure 7: Global: Oncology Based In-Vivo CRO Market: Breakup by Region (in %), 2025
Figure 8: Global: Oncology Based In-Vivo CRO (Blood Cancer) Market: Sales Value (in Million USD), 2020 & 2025
Figure 9: Global: Oncology Based In-Vivo CRO (Blood Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 10: Global: Oncology Based In-Vivo CRO (Solid Tumors) Market: Sales Value (in Million USD), 2020 & 2025
Figure 11: Global: Oncology Based In-Vivo CRO (Solid Tumors) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 12: Global: Oncology Based In-Vivo CRO (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
Figure 13: Global: Oncology Based In-Vivo CRO (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 14: Global: Oncology Based In-Vivo CRO (Syngeneic) Market: Sales Value (in Million USD), 2020 & 2025
Figure 15: Global: Oncology Based In-Vivo CRO (Syngeneic) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 16: Global: Oncology Based In-Vivo CRO (Xenograft) Market: Sales Value (in Million USD), 2020 & 2025
Figure 17: Global: Oncology Based In-Vivo CRO (Xenograft) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 18: Global: Oncology Based In-Vivo CRO (Patient Derived Xenograft (PDX)) Market: Sales Value (in Million USD), 2020 & 2025
Figure 19: Global: Oncology Based In-Vivo CRO (Patient Derived Xenograft (PDX)) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 20: Global: Oncology Based In-Vivo CRO (Other Models) Market: Sales Value (in Million USD), 2020 & 2025
Figure 21: Global: Oncology Based In-Vivo CRO (Other Models) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 22: Global: Oncology Based In-Vivo CRO (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
Figure 23: Global: Oncology Based In-Vivo CRO (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 24: Global: Oncology Based In-Vivo CRO (Rehabilitation Centers) Market: Sales Value (in Million USD), 2020 & 2025
Figure 25: Global: Oncology Based In-Vivo CRO (Rehabilitation Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 26: North America: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 27: North America: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 28: United States: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 29: United States: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 30: Canada: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 31: Canada: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 32: Asia-Pacific: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 33: Asia-Pacific: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 34: China: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 35: China: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 36: Japan: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 37: Japan: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 38: India: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 39: India: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 40: South Korea: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 41: South Korea: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 42: Australia: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 43: Australia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 44: Indonesia: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 45: Indonesia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 46: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 47: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 48: Europe: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 49: Europe: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 50: Germany: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 51: Germany: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 52: France: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 53: France: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 54: United Kingdom: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 55: United Kingdom: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 56: Italy: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 57: Italy: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 58: Spain: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 59: Spain: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 60: Russia: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 61: Russia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 62: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 63: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 64: Latin America: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 65: Latin America: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 66: Brazil: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 67: Brazil: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 68: Mexico: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 69: Mexico: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 70: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 71: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 72: Middle East and Africa: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 73: Middle East and Africa: Oncology Based In-Vivo CRO Market: Breakup by Country (in %), 2025
Figure 74: Middle East and Africa: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 75: Global: Oncology Based In-Vivo CRO Industry: SWOT Analysis
Figure 76: Global: Oncology Based In-Vivo CRO Industry: Value Chain Analysis
Figure 77: Global: Oncology Based In-Vivo CRO Industry: Porter's Five Forces Analysis
Figure 1: Global: Oncology Based In-Vivo CRO Market: Major Drivers and Challenges
Figure 2: Global: Oncology Based In-Vivo CRO Market: Sales Value (in Billion USD), 2020-2025
Figure 3: Global: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Billion USD), 2026-2034
Figure 4: Global: Oncology Based In-Vivo CRO Market: Breakup by Indication (in %), 2025
Figure 5: Global: Oncology Based In-Vivo CRO Market: Breakup by Model (in %), 2025
Figure 6: Global: Oncology Based In-Vivo CRO Market: Breakup by Application (in %), 2025
Figure 7: Global: Oncology Based In-Vivo CRO Market: Breakup by Region (in %), 2025
Figure 8: Global: Oncology Based In-Vivo CRO (Blood Cancer) Market: Sales Value (in Million USD), 2020 & 2025
Figure 9: Global: Oncology Based In-Vivo CRO (Blood Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 10: Global: Oncology Based In-Vivo CRO (Solid Tumors) Market: Sales Value (in Million USD), 2020 & 2025
Figure 11: Global: Oncology Based In-Vivo CRO (Solid Tumors) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 12: Global: Oncology Based In-Vivo CRO (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
Figure 13: Global: Oncology Based In-Vivo CRO (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 14: Global: Oncology Based In-Vivo CRO (Syngeneic) Market: Sales Value (in Million USD), 2020 & 2025
Figure 15: Global: Oncology Based In-Vivo CRO (Syngeneic) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 16: Global: Oncology Based In-Vivo CRO (Xenograft) Market: Sales Value (in Million USD), 2020 & 2025
Figure 17: Global: Oncology Based In-Vivo CRO (Xenograft) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 18: Global: Oncology Based In-Vivo CRO (Patient Derived Xenograft (PDX)) Market: Sales Value (in Million USD), 2020 & 2025
Figure 19: Global: Oncology Based In-Vivo CRO (Patient Derived Xenograft (PDX)) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 20: Global: Oncology Based In-Vivo CRO (Other Models) Market: Sales Value (in Million USD), 2020 & 2025
Figure 21: Global: Oncology Based In-Vivo CRO (Other Models) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 22: Global: Oncology Based In-Vivo CRO (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
Figure 23: Global: Oncology Based In-Vivo CRO (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 24: Global: Oncology Based In-Vivo CRO (Rehabilitation Centers) Market: Sales Value (in Million USD), 2020 & 2025
Figure 25: Global: Oncology Based In-Vivo CRO (Rehabilitation Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 26: North America: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 27: North America: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 28: United States: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 29: United States: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 30: Canada: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 31: Canada: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 32: Asia-Pacific: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 33: Asia-Pacific: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 34: China: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 35: China: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 36: Japan: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 37: Japan: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 38: India: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 39: India: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 40: South Korea: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 41: South Korea: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 42: Australia: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 43: Australia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 44: Indonesia: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 45: Indonesia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 46: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 47: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 48: Europe: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 49: Europe: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 50: Germany: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 51: Germany: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 52: France: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 53: France: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 54: United Kingdom: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 55: United Kingdom: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 56: Italy: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 57: Italy: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 58: Spain: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 59: Spain: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 60: Russia: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 61: Russia: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 62: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 63: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 64: Latin America: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 65: Latin America: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 66: Brazil: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 67: Brazil: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 68: Mexico: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 69: Mexico: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 70: Others: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 71: Others: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 72: Middle East and Africa: Oncology Based In-Vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
Figure 73: Middle East and Africa: Oncology Based In-Vivo CRO Market: Breakup by Country (in %), 2025
Figure 74: Middle East and Africa: Oncology Based In-Vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 75: Global: Oncology Based In-Vivo CRO Industry: SWOT Analysis
Figure 76: Global: Oncology Based In-Vivo CRO Industry: Value Chain Analysis
Figure 77: Global: Oncology Based In-Vivo CRO Industry: Porter's Five Forces Analysis
